Ellume Appoints CFO And CBO

  • On April 23, 2019
Brisbane, Australia – 23rd April 2019 Ellume Limited (Ellume) is pleased to announce the appointment of David Green as Chief Financial Officer and Company Secretary, and Mark Boyle Chief Business Officer of the Company. These appointments strengthen the management of the company in preparation for US commercialisation and potential ASX IPO later this year. David […]
Read More

Ellume announces another global partnership – this time with QIAGEN on the detection of tuberculosis

  • On January 8, 2019
Highlights Australia’s Ellume Limited has partnered with QIAGEN N.V. to bring the next generation of latent TB testing to low-resource, high-burden countries The deal includes the licensing of Ellume technologies and a USD $15M minority investment by QIAGEN in Ellume Limited This announcement builds on the recent announcement of a global partnership with GlaxoSmithKline announced […]
Read More

Medical diagnostics firm Ellume gets German backing for TB testing

  • On January 7, 2019
7 January 2019, Peter Williams This article originally appeared in The Australian, print and online, on 7th January 2019. View the original here on The Australian Website. Brisbane medical diagnostics company Ellume has received a $US15 million ($21m) investment from German biotech Qiagen as part of a broader strategic partnership between the two companies to detect tuberculosis. Clinical trials for a […]
Read More

Ellume spreads global wings with GSK deal

  • On December 11, 2018
11 December 2018, Sarah-Jane Tasker This article originally appeared in The Australian, print and online, on 11th December 2018. View the original here on The Australian Website. Brisbane medical diagnostics company Ellume has signed a significant deal with pharmaceutical giant GSK for digital consumer products, ahead of a potential market listing. Ellume founder and managing directory Sean Parsons said the […]
Read More